Citations

Clear

11 citation(s) found for "Anderson, Lauren".

Addition of Metastasis-Directed Therapy to Standard of Care for Oligometastatic Disease: Primary Aggregated Analysis of All Baskets from the Phase II Randomized EXTEND Trial
Sherry, Alexander D. , Haymaker, C, Wang, S, Liu, S, Medina-Rosales, Marina Nayeli , Seo, Aaron, Reddy, Jay P. , Mayo, Lauren L., Pant, Shubham , Kovitz, Craig A., Ha, Chul S., Smith, BD, Gomez, Daniel, Cohen, Lorenzo , Tannir, Nizar, Corn, Paul G., Siddiqui, Bilal A. , Ludmir, Ethan B., Tang, Chad , Haymaker, Cara , Liu, Suyu , Haymaker, Cara , Wang, Shuqi , Liu, Suyu , Bathala, Tharakeswara K , Medina-Rosales, Marina N , Reddy, Jay P , Chun, Stephen G , Walker, Gary , Pant, Shubham , Zhao, Dan , Kovitz, Craig A , Smith, Benjamin D , Gomez, Daniel , Cohen, Lorenzo , Koong, Albert C , Reuben, Alexandre , Tannir, Nizar , Tran, Phuoc T , Siddiqui, Bilal A , Subudhi, Sumit Kumar , Msaouel, Pavlos , Ludmir, Ethan B , Tang, Chad , Sherry, Alexander D , Seo, Aaron , Hara, Kieko , Chun, Stephen G. , Mayo, Lauren L. , Zhao, Dan , Ramirez, David Luis , Ha, Chul S. , Corn, Paul Gettys , Msaouel, Pavlos , Ludmir, Ethan B.

Mayo Clinic

Journal of Clinical Oncology | May 16, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1200/jco-25-02856 | PMID 42142259 Get It

PURPOSE We tested the hypothesis that adding metastasis-directed therapy (MDT) to standard-of-care (SOC) systemic therapy improves progression-free survival (PFS) among patients with oligometastatic disease. METHODS EXTEND was a multicenter randomized phase II trial. Patients with 1-5 metastases were randomly assigned to MDT + SOC versus SOC in one of the six baskets (breast, pancreas, kidney, two prostate baskets, and an other basket) with basket-specific stratification and powering. PFS, the primary end point, was prespecified in the per-protocol set within each basket, across all baskets, and across all baskets excluding the prostate baskets. Exploratory end points included circulating tumor DNA (ctDNA) and immune profiling. RESULTS From 2018 through 2023, 521 patients were screened, 350 were randomly assigned, and 334 were analyzed per protocol (MDT + SOC, n = 166; SOC, n = 168). Radiotherapy was used as MDT for 98% of metastases (370/379). Overall, after a median follow-up of 53 months, PFS was improved with MDT + SOC (hazard ratio [HR], 0.54 [95% CI, 0.41 to 0.72], P < .001). Similarly, PFS was improved when excluding the prostate baskets (HR, 0.60 [95% CI, 0.40 to 0.89]). Within each basket, PFS superiority was identified for the pancreas, prostate, and other baskets, whereas the breast and kidney baskets were inconclusive. At enrollment, detectable ctDNA correlated with shorter PFS and survival; by contrast, ctDNA clearance 3 months postenrollment correlated with improved survival. MDT + SOC-induced systemic immune activation was most pronounced among baskets demonstrating PFS superiority. CONCLUSION The phase II EXTEND trial supports the addition of MDT to SOC for oligometastatic disease. Histology-specific efficacy signals were identified for phase III testing. Translational insights suggest the potential for optimizing the definition of oligometastasis using ctDNA and point to systemic immune responses as a possible mechanism of benefit from MDT.
Adopting Race‐Free Estimated Glomerular Filtration Rate for Unifying Medication‐Related Decision‐Making: An Opinion of the Nephrology Practice and Research Network of the American College of Clinical Pharmacy
Wallace, J. , Rungkitwattanakul, Dhakrit , Khan, Rachel W. , Anderson, Lauren , Anderson, Erica , Nekidy, Wasim S. El , Nemecek, Branden D. , Meaney, Calvin J. , Prasad‐Reddy, Lalita , Salama, Lavinia , Hudson, Joanna Q. , Kane‐Gill, Sandra L. , Frazee, Erin N. , Anderson, Erica R , El Nekidy, Wasim S , Frazee, Erin N , Bzowyckyj, Andrew S , Kane-Gill, Sandra L , Peter, Wendy L. St.

Mayo Clinic

JACCP: JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY | November 27, 2025 | Volume: 9 | Issue: 2 | Pages: No page available

10.1002/jac5.70153 | PMID 42009503 Get It

ABSTRACT Pharmacists play a critical role in optimizing medication use, especially in vulnerable populations such as those with chronic kidney disease (CKD). Despite strong evidence and recent guideline endorsements, many pharmacists continue to rely on the Cockcroft–Gault (C‐G) equation for medication dosing. This opinion paper issues a call to action for the widespread adoption of a race‐free, body surface area–adjusted estimated glomerular filtration rate (eGFR BSAadj ) for medication‐related decision‐making, as endorsed by the 2024 Kidney Disease: Improving Global Outcomes CKD guidelines and the National Kidney Foundation and the American Society of Nephrology Taskforce. Persistent variability in pharmacy practice, institutional protocols, and pharmacy education underscores the need for coordinated change. We urge health systems to integrate eGFR BSAadj into electronic health records and clinical decision support to enhance medication decision‐making; institutions to align protocols with contemporary eGFR‐based prescribing standards; pharmacy educators to contemporize and standardize education on kidney function assessment and medication dosing; and regulatory bodies to update licensure and board examinations. The pharmacy profession must act decisively in order to align with evidence‐based, equitable kidney‐related dosing practices and ensure optimal medication management for all patients.
Metastasis-directed therapy (MDT) plus androgen deprivation therapy (ADT) for oligometastatic prostate cancer (omPC): Primary results of the EXTEND continuous ADT (cADT) basket plus combined analysis with the updated intermittent ADT (iADT) basket and immu
Fellman, Bryan , Mayo, Lauren L. , Choi, Seungtaek , Phillips, Ryan, Deek, Matthew P. , Zurita, Amado J. , Siddiqui, Bilal A. , Tang, Chad , Sherry, Alexander D. , Haymaker, Cara , Bathala, Tharakeswara K , Medina-Rosales, Marina N , Liu, Suyu , Chun, Stephen G. , Aparicio, Ana M , Pilie, Patrick Glen , Siddiqui, Bilal A , Subudhi, Sumit Kumar , Reuben, Alexandre , Corn, Paul Gettys , Tran, Phuoc T , Tang, Chad

Mayo Clinic

Journal of Clinical Oncology | February 18, 2025 | Volume: 43 | Issue: 5_suppl | Pages: 140-140

10.1200/jco.2025.43.5_suppl.140 Get It

140 Background: In the phase II EXTEND iADT omPC basket, MDT+iADT improved progression-free survival (PFS) vs iADT. Here we present the primary results of the EXTEND cADT omPC basket. We further report a pre-specified combined analysis with updated results from the iADT basket and examine the effects of MDT on immunity. Methods: Patients with 1 to 5 omPC metastases were randomized 1:1 to MDT+cADT vs cADT (NCT03599765). MDT consisted of definitive local therapy. cADT consisted of ADT +/- second-generation anti-androgens. The primary endpoint was per-protocol PFS, defined by biochemical criteria (Prostate Cancer Working Group 3), radiologic measures (RECIST v1.1), clinical progression, or death. 87 patients were needed to show superiority at a one-sided P of 0.10 by log-rank test. CDR3 regions in rearranged T cell receptor (TCR) β-chains from pre- and post-enrollment peripheral blood were sequenced with immunoSEQ (Adaptive Biotech). TCR repertoire modulation was defined as having TCR expansion plus contraction using a false-discovery-corrected betabinomial model. TCR sequencing from the ORIOLE trial (NCT02680587) was assessed for external validation. Results: From 2018 to 2022, 87 randomized patients were treated per protocol (MDT+cADT: 45; cADT: 42). 39% had castrate resistant omPC. MDT was definitive radiotherapy in all cases. With median follow-up of 31 mo, median PFS was 47 mo after MDT+cADT vs 22 mo after cADT (HR 0.50; 95% CI 0.23 to 1.08; one-sided P = 0.036). In the combined analysis (N=174) with median follow-up of 42 mo, MDT+ADT improved PFS (HR 0.45; 95% CI 0.30 to 0.69; P < 0.001), radiologic PFS (HR 0.63; 95% CI 0.40 to 0.97; P = 0.038), and castration-resistance free-survival (HR 0.40; 95% CI 0.19 to 0.82; P = 0.013). MDT+ADT had higher odds of TCR repertoire modulation vs ADT (55% vs 15%, P < 0.001). This finding was validated in the ORIOLE trial (MDT: 57% vs observation: 19%, P = 0.03). Among the subset of patients with extreme responses, random forest modeling of 37 clinical/immune variables identified TCR repertoire modulation as the variable with highest importance; further, MDT+ADT induced TCR repertoire modulation in all patients with favorable responses (i.e. PFS > 4 years) and none with unfavorable responses (i.e. PFS < 1 year). Among all patients randomized to MDT+ADT, TCR repertoire modulation was associated with longer PFS (HR 0.21; 95% CI 0.06 to 0.76; P = 0.02). Conclusions: MDT+cADT met the PFS primary endpoint of the phase II EXTEND trial, warranting phase III testing. From the combined analysis, MDT+ADT may also improve longer term outcomes including radiologic PFS and castration-resistance-free survival. Improved outcomes may result from MDT-induced immunomodulation, with implications for future trial design. Clinical trial information: NCT03599765 .
Perceptions of Clinical Trials and Factors Influencing Trial Participation Among Hispanic Patients with Non-Hodgkin Lymphoma
Romero, Alexis, Nguyen, Sophia, Ayers, Amy , Chen, Minxing , Yzquierdo, Rebecca, Rahman, Adiya, Johnson, Lauren, Vickers, Tiffany, Wafi, Zeinab, Flowers, Christopher R. , Romero, Alexis, Andersen, Clark R. , Rahman, Adiya, Johnson, Lauren, Vickers, Tiffany, McNeill, Lorna Haughton. , Cerhan, James R. , Nze, Chijioke

Mayo Clinic

Blood | December 6, 2024 | Volume: 144 | Issue: Supplement 1 | Pages: 3733-3733

10.1182/blood-2024-211657 Get It

Background Hispanic patients continue to be underrepresented in clinical trials. To better understand the factors that impact clinical trial participation, we surveyed patients with NHL receiving care at an academic institution on their perspectives on clinical trials, barriers to care, and helpful aids to encourage clinical trial participation. Here we report the findings of the Hispanic patients and non-Hispanic white patients; accrual is ongoing for other cohorts of patients. Methods Consecutive patients ≥ 18 years old with histologically confirmed NHL who received care at MD Anderson Cancer Center in the Texas Medical Center in Houston, Texas were invited to participate regardless of treatment status. A self-administered questionnaire was used to assess patient sociodemographic factors, perceptions and willingness to participate in different clinical trial scenarios as well as participant perceived barriers to care and facilitators of trial participation. The questionnaire included a total of 53 items with an additional 13 demographic items. The questionnaire was available in English and Spanish. Results Of the 1204 patients invited, 316 consented to participate and 285 ultimately completed the survey (participation rate 23.7%). Among the total participants, this cohort included 100 self-identified Hispanic (H) participants and 103 non-Hispanic white (NHW) participants diagnosed with NHL who completed the survey and were included here. The histology of our cohort included Follicular Lymphoma (FL) [35.6%]; Diffuse Large B-cell lymphoma (DLBCL) [18.2%], Mantle cell lymphoma (MCL) [18.7%], T-cell Lymphoma (TCL) [9.4%] Marginal Zone Lymphoma [7.8%]. Compared with NHW participants, Hispanic patients were younger (Median age of 60 vs 66 years), less likely to be male (H 54% vs NHW 66%), less likely to commute more than an hour away from the doctor's office (54% vs 71.8%), had lower household income (income &gt; $100,000 was 32% vs 41.7%) and less likely to have a bachelors' degree or higher (38% vs 50.5%). There were similar prevalence histologies such as DLBCL (H 20% vs NHW 16.5%) and FL (H 36% vs NHW 35%) compared to rarer histologies such as MCL (H 11.1% vs NHW 26.2%) and MZL (H 12% vs NHW 3.9% ) which had disproportional prevalences. Hispanic patients were less likely to have previously participated in a clinical trial (28% vs 51.5%) and less likely to have discussed clinical trials as an option (49% vs 70.9%). A majority of Hispanic (81.0%) and NHW (92.3%) respondents stated that they understood what was meant by a “clinical research study” or “clinical trial” somewhat well or very well. Less than half of Hispanic participants (38.0%) and NHW participants (48.5%) reported being very willing to participate in a cancer clinical trial as their initial course of treatment. The most prevalent concern of both Hispanic and NHW participants respectively was the cost of a clinical trial (34.0%, 22.3%). Other top concerns included distance to the treatment center (32.0%, 13.6%) and frequency of contact with the care team (26.0%, 14.6%). Participants identified access to written materials (69.0%, 60.2%), insurance aid (65.0%, 68.0%), and access to videos (64.0%, 51.5%) as extremely helpful resources that could reduce the burden of participating in a clinical trial. Participants identified that it was most important that a treatment may improve their quality of life by decreasing pain level, increasing activity level, or other symptoms (76.0%, 91.3%). Conclusions Although most Hispanic and NHW participants reported a very good understanding of clinical trials and similar facilitators/barriers for trial participation, Hispanic patients were less likely to have discussed trials as an option with their care teams and less likely to have previously participated in a trial. Evidence-based interventions to address various barriers to clinical trials exist but data on their effectiveness and application is limited. Implementing strategically designed evidence-based interventions to address identified barriers and facilitators will be necessary to improve participation in lymphoma clinical trials.
SWOG S2012: Randomized phase II/III trial of first line platinum (P)/etoposide (E) with or without atezolizumab (NSC #783608) in patients with advanced or metastatic poorly differentiated extrapulmonary neuroendocrine carcinomas (NEC).
Moseley, Anna , Chiorean, E. Gabriela , Gay, Carl M. , Byers, Lauren A. , Wistuba, Ignacio I. , Mahdi, Haider , Starr, Jason S. , Chae, Young Kwang , Zhen, David B. , Burgess, Earle F. , Swisher, Elizabeth M. , Othus, Megan , Kurzrock, Razelle

Mayo Clinic

Journal of Clinical Oncology | July 3, 2024 | Volume: 42 | Issue: 16_suppl | Pages: TPS4201-TPS4201

10.1200/jco.2024.42.16_suppl.tps4201 Get It

TPS4201 Background: Poorly differentiated, extrapulmonary NEC are rare cancers with median overall survival (OS) <1 year. Treatment is extrapolated from small cell lung cancer (SCLC) with use of P (cisplatin or carboplatin) + E. More effective treatment regimens and predictive biomarkers are needed to improve outcomes. In SCLC, induction therapy with combination of P/E + PD-L1 checkpoint inhibitor atezolizumab and maintenance atezolizumab improved OS (12.3 months vs 10.3 months; HR 0.70, 95% CI 0.54 – 0.91, P=0.007) vs P/E alone (1). No study to date has compared PD-1/PD-L1 inhibition during induction only vs during induction and maintenance therapy. In SCLC, distinct molecular subtypes can be identified by the presence of specific transcription factors (e.g., ASCL1, NEUROD1, POU2F3) or an inflamed gene signature (SCLC-I), with SCLC-I pts more likely to benefit clinically from the addition of immunotherapy (2). In this study we plan to test the benefit of adding atezolizumab to induction P/E as well as the role of adding maintenance atezolizumab after induction P/E plus atezolizumab. We also plan to correlate tumor- and blood-based subtype biomarkers with response to therapy. Methods: Eligible pts ≥18 years old have evaluable, histologically confirmed extrapulmonary NEC, Zubrod PS ≤2, and are allowed to have up to 1 cycle of P/E prior to enrollment. P (cisplatin 75 mg/m2 or carboplatin AUC 5, iv) on day 1, E 100 mg/m2 iv on days 1-3, and atezolizumab 1200 mg iv on day 1 of q21 day cycles. Pts are randomized to 1 of 3 arms: A) Induction P/E + atezolizumab -> maintenance atezolizumab B) Induction P/E + atezolizumab -> observation C) Induction P/E -> observation. The primary objective is to compare the overall survival (OS, from randomization) between arms in a fixed sequence: A vs C -> B vs C -> A vs B. Secondary objectives include comparing OS (from start of maintenance/observation), progression free survival, response rate, duration of response, and safety/tolerability across arms. Tumor and blood samples will be banked for future biomarker analyses, including immunohistochemistry of transcription factors on tissue and whole exome sequencing on tumor and circulating tumor DNA. With 189 pts (168 eligible), the study has 84% power to detect an improvement in 12-months OS from 35% to 57.5% (HR 0.53). This study was activated December 2021 with 3 pts enrolled over 1 year due to restricting enrollment of NEC of small cell histology only. The protocol was amended in January 2023 to broaden eligibility to all NEC subtypes (small cell, large cell, and undefined histology with Ki-67 ≥55%). As of January 2024, 35 patients have been enrolled. A protocol amendment is planned to remove the need for Ki-67 index for NEC of genitourinary origin to improve accrual. 1. Horn L, et al. N Engl J Med 2018. 2. Gay CM, et al. Cancer Cell 2021. Clinical trial information: NCT05058651 .
Impacts of genesurance considerations on genetic counselors' practice and attitudes
Thoreson, Emily , Murphy, Lauren , Lemons, Jennifer, Farach, Laura S. , Wilson, Kate , Woodson, Ashley, Wagner, Chelsea

Mayo Clinic

Journal of Genetic Counseling | May 20, 2020 | Volume: 29 | Issue: 6 | Pages: 1210-1220

10.1002/jgc4.1291 | PMID 32432815 Get It

AbstractGenesurance counseling has been identified as an integral part of many genetic counseling sessions, but little is known about the workflow impacts and genetic counselor perceptions of genesurance‐related tasks. In this study, we aimed to characterize how insurance and billing considerations for genetic testing are being incorporated into genetic counselors' practice in the United States, as well as describe current attitudes and challenges associated with their integration. An electronic survey was sent by email to members of the National Society of Genetic Counselors (NSGC). A total of 325 American Board of Genetic Counselors‐certified genetic counselors who provide direct patient care in the United States for at least 50% of their time were included in data analysis. Results showed that the frequency and timing of various insurance‐ and billing‐related tasks were not consistent among respondents, even those practicing in similar settings. Inadequate training to complete tasks was reported by 64% of respondents, and 47% reported a lack of resources from their employer and/or institution to complete genesurance tasks. Additionally, only 38% of respondents agreed that insurance‐ and billing‐related tasks were within the scope of the genetic counseling practice, and there was little consensus on who respondents believe is the most appropriate person to complete these tasks. When asked how genesurance considerations affected job satisfaction, 85% of respondents reported a negative impact. This study found an inconsistent genesurance workflow among genetic counselors practicing in the United States, a lack of consensus on who should be responsible for genesurance tasks, several challenges associated with completing these tasks, and identifies genesurance considerations as potential risk factors for genetic counselor burnout.
ZEB1 suppression sensitizes KRAS mutant cancers to MEK inhibition by an IL17RD-dependent mechanism
Peng, David H. , Kundu, Samrat T. , Fradette, Jared J. , Diao, Lixia , Tong, Pan, Byers, Lauren A. , Wang, Jing , Canales, Jaime Rodriguez, Villalobos, Pamela, Mino, Barbara , Yang, Yanan , Minelli, Rosalba, Peoples, Michael , Bristow, Christopher A. , Heffernan, Timothy P. , Carugo, Alessandro , Wistuba, Ignacio I. , Peoples, Michael D , Gibbons, Don L , Yang, Yanan

Mayo Clinic

Science Translational Medicine | March 13, 2019 | Volume: 11 | Issue: 483 | Pages: No page available

10.1126/scitranslmed.aaq1238 | PMID 30867319 Get It

Suppression of ZEB1 through miR-200 expression or HDAC inhibition with mocetinostat sensitizes resistant KRAS mutant lung cancers to MEK inhibition.
Abstract 4137: Loss of LKB1 mediates an immune inert phenotype in human lung adenocarcinoma
Skoulidis, Ferdinandos , Papadimitrakopoulou, Vassiliki A. , Diao, Lixia , Lou, Yanyan , Byers, Lauren A. , Wang, Jing , Canales, Jaime Rodriguez, Wistuba, Ignacio I. , Heymach, John V. , Denning, Warren L. , Shen, Li , Weinstein, John N. , Gibbons, Don L , Heymach, John V

Mayo Clinic

Cancer Research | July 26, 2016 | Volume: 76 | Issue: 14_Supplement | Pages: 4137-4137

10.1158/1538-7445.am2016-4137 Get It

Abstract Background: We recently have reported that co-mutations within KRAS-mutated lung adenocarcinoma (LUAD) define a distinct biological phenotype and may offer insights into therapeutic targeting using this classification system. The analysis revealed striking differences in checkpoint ligand expression and T cell infiltration between TP53 and STK11 (LKB1) co-mutated KRAS LUAD. We, therefore, hypothesized that loss of LKB1promotes an immune-suppressed phenotype in KRAS LUAD. To test this, we analyzed 100 immune-related genes from The Cancer Genome Atlas datasets, as well as three other sets of resected tumors from NSLC patients from MD Anderson Cancer Center. Results: Our results revealed that tumors lacking LKB1 (LKB1-loss), as defined by mutation or gene-expression signature, resulted in a down regulation of: tumor associated immunosuppressive ligands, PD-L1, PD-L2, B7-H3, B7-H4, HVEM; T cell associated immunosuppressive ligands PD-1, CTLA-4, BTLA; co-stimulation ligands such as CD80, -86, -40L, and -40. We further examined if this loss of immunosuppression and co-stimulation resulted in changes in markers of T cell phenotypes. Indeed, tumors lacking LKB1-loss tumors demonstrated a distinct lack absence of several T cell markers including CD3, -4, & -8, but also RORC, T-bet, GATA-3, and FoxP3. To determine if myeloid cell populations, known mediators of immune suppression, were also diminished in LKB1-loss tumors, we analyzed expression of CD11c, -103, -11b, -68, and CD33. Consistent with T cell makers and suppressive ligand markers, myeloid markers were down regulated in LKB1-loss tumors. Because common immune suppression markers were lost, we then examined the expression of antigen presentation (HLA-I, HLA-II) and amino acid transporters as possible alternative methods for immune suppression. In LKB1-loss tumors, both HLA-I and HLA-II markers were down regulated, compared to tumors with intact LKB1 expression. Furthermore, genes associated with the antigen presentation complex, LMP2, TAP1&2, and B2M were also down regulated. In contrast to the immune markers described above, cationic transporters (SLC7A2), anionic transporters (SLC7A11), and neutral transporters (SLC3A2) were universally upregulated in LKB1-loss tumors. Conclusions: LKB1 loss is associated with an inert immune phenotype. Our data suggests that reduced antigen presentation and amino acid depletion, but not checkpoint factors or MDSCs, are likely mediator of this phenotype. Citation Format: Warren L. Denning, Ferdinandos Skoulidis, Li Shen, Vassiliki Papadimitrakopoulou, Lixia Diao, Yanyan Lou, Lauren A. Byers, Jing Wang, Jaime R. Canales, Ignacio I. Wistuba, John Weinstein, Don L. Gibbons, John V. Heymach. Loss of LKB1 mediates an immune inert phenotype in human lung adenocarcinoma. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 4137.
National Randomized Controlled Trial of Virtual House Calls for People with Parkinson's Disease: Interest and Barriers
Dorsey, E. Ray , Achey, Meredith A. , Beck, Christopher A. , Beran, Denise B., Biglan, Kevin , Boyd, Cynthia M. , Schmidt, Péter , Simone, Richard, Willis, Allison W. , Galifianakis, Nicholas B. , Katz, Maya , Dodenhoff, Kristen A. , Ziman, Nathan, Aldred, Jason , Carter, Julie, Jimenez‐Shahed, Joohi , Hunter, Christine , Spindler, Meredith , Morgan, John C. , McLane, Dedi, Hickey, Patrick , Gauger, Lisa, Richard, Irene Hegeman, Bull, Michael, Mejia, Nicte I. , Bwala, Grace, Nance, Martha , Shih, Ludy C. , Anderson, Lauren , Singer, Carlos , Zadikoff, Cindy , Okon, Natalia, Feigin, Andrew, Ayan, J., Vaughan, Christina , Cooper, Jessica , Webb, S. J., Dhall, Rohit , Hassan, Anhar , Weis, Delana, DeMello, Steven, Smith, Joseph M. , Keenan, H. Tait, Korn, Ryan, Schwarz, Heidi B., Stevenson, E. Anna , Zhu, William , Tanner, Caroline M. , Mari, Zoltan K. , Pahwa, Rajesh , Riggare, Sara S. , Wicks, Paul J , Sharma, Saloni , Jimenez-Shahed, Joohi

Mayo Clinic

Telemedicine and e-Health | February 17, 2016 | Volume: 22 | Issue: 7 | Pages: 590-598

10.1089/tmj.2015.0191 | PMID 26886406 Get It

Background: Delivering specialty care remotely directly into people's homes can enhance access for and improve the healthcare of individuals with chronic conditions. However, evidence supporting this approach is limited. Materials and Methods: Connect.Parkinson is a randomized comparative effectiveness study that compares usual care of individuals with Parkinson's disease in the community with usual care augmented by virtual house calls with a Parkinson's disease specialist from 1 of 18 centers nationally. Individuals in the intervention arm receive four virtual visits from a Parkinson's disease specialist over 1 year via secure, Web-based videoconferencing directly into their homes. All study activities, including recruitment, enrollment, and assessments, are conducted remotely. Here we report on interest, feasibility, and barriers to enrollment in this ongoing study. Results: During recruitment, 11,734 individuals visited the study's Web site, and 927 unique individuals submitted electronic interest forms. Two hundred ten individuals from 18 states enrolled in the study from March 2014 to June 2015, and 195 were randomized. Most participants were white (96%) and college educated (73%). Of the randomized participants, 73% had seen a Parkinson's disease specialist within the previous year. Conclusions: Among individuals with Parkinson's disease, national interest in receiving remote specialty care directly into the home is high. Remote enrollment in this care model is feasible but is likely affected by differential access to the Internet.
Hashimoto Thyroiditis: Part 2, Sonographic Analysis of Benign and Malignant Nodules in Patients With Diffuse Hashimoto Thyroiditis
Anderson, Lauren , Middleton, William D. , Teefey, Sharlene A. , Reading, Carl C., Langer, Jill E. , Desser, Terry S. , Szabunio, Margaret M. , Mandel, Susan J., Hildebolt, Charles F. , Cronan, John J.

Mayo Clinic

American Journal of Roentgenology | June 21, 2010 | Volume: 195 | Issue: 1 | Pages: 216-222

10.2214/ajr.09.3680 | PMID 20566819 Get It